Housed in the Indiana Center for Biomedical Innovation in Indianpolis, IN., HB Therapeutics is an early stage biotech company structured around discovery and development of small molecule degraders inducing ubiquitination and degradation of oncoproteins. The first degraders of small ubiquitin-like modifier (SUMO1) protein are now in preclinical stage and several small molecule degraders of other oncoproteins are in the company pipeline for development of new classes of anticancer drugs.
